<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Le Heuzey, Jean-Yves</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Anticoagulation and Antithrombotic Therapy in Atrial Fibrillation</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">32-33</style></pages><abstract><style  face="normal" font="default" size="100%">Patients with atrial fibrillation (AF) have a 5-fold risk of stroke and suffer more severe strokes compared with the general population [Camm AJ et al. Eur Heart J 2010]. One-year mortality in stroke patients with AF is 63% versus 34% in those without AF (p&lt;0.001) [Lin H-J et al. Stroke 1996]. The risk of stroke recurrence is slightly higher in patients with AF (6.9% vs 4.7% in those without AF; p=0.0398) [Marini C et al. Stroke 2005].</style></abstract><number><style face="normal" font="default" size="100%">13</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>